Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Market Edge
|
$10.00
|
|
Provider: GlobalData
|
$250.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$115.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Mindray Medical International Ltd Revises FY 2013 Revenue Guidance To A Range In Line With Analysts' Estimates; Lowers FY 2012 Net Income Guidance; Comments On FY 2013 Revenue Guidance
Mindray Medical International Ltd announced that for fiscal 2012, it expects net revenue to be approximately USD1.056 billion. Based on the estimated full-year revenue, the company anticipates fiscal 2012 non-GAAP net income to be approximately USD207 million. Fiscal 2013, the Company expects revenue to grow at least 17% year-over-year, with China and other emerging markets as the primary growth contributors. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $1.055 billion and net income of $197 million for fiscal 2012; revenue of $1.244 billion for fiscal 2013.
Latest Developments for Mindray Medical International Ltd
- Mindray Medical International Ltd Reaffirms FY 2013 Guidance
- Mindray Medical International Ltd Reaffirms FY 2013 Revenue Guidance; Issues FY 2013 Net Income Guidance Above Analysts' Estimates; Declares Cash Dividend
- Mindray Medical International Ltd Initiates a Voluntary Recall Affecting A3/A5 Anesthesia Delivery System
- Mindray Medical International Ltd Reaffirms FY 2012 Guidance; Announces Top Management Change
Latest Key Developments in Advanced
- Hologic Inc Receives FDA Approval For New Low-dose 3D Mammography (Breast Tomosynthesis) Solution For Breast Cancer Screening
- Echo Therapeutics Inc Announces Institutional Review Board (IRB) Approval For Clinical Trial Of Symphony CGM System
- Neovasc Inc Announces Registry Data Presented At Europcr 2013 Confirms the Neovasc Reducer Improves Cardiovascular Parameters In Refractory Angina Patients
- Elekta AB's Chairman Akbar Seddigh Declines Reelection
- Share this
- Link this
- Digg this


Follow Reuters